Southwest Airlines Co vs Medpace Holdings Inc — how do they compare? Southwest Airlines Co trades at $48.24 (market cap $23.63B), while Medpace Holdings Inc trades at $530.22 (market cap $15.08B). The key difference: Southwest Airlines Co is the larger of the two by market cap, and Southwest Airlines Co pays a 1.49% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| LUV | MEDP | |
|---|---|---|
Market Cap | $23.63B | $15.08B |
Sector | Industrials | Technology |
52-Week High | $54.80 | $620.59 |
52-Week Low | $29.06 | $308.88 |
Enterprise Value | $26.70B | $14.55B |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Trailing returns across standard periods
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →